What to use in patients with ischaemic heart disease and atrial fibrillation – anticoagulation, antiaggregation or both?

Česká verzia

Authors: R. Lábrová; J. Špinar
Authors place of work: Interní kardiologická klinika LF MU a FN Brno
Published in the journal: Kardiol Rev Int Med 2016, 18(1): 47-51
Category: Cardiology Review

Summary

A combination of atrial fibrillation and ischaemic heart disease is quite common and antiaggregation or anticoagulation treatment should improve the prognosis of the patients. However, clear evidence is missing and recommendations contained in official guidelines sometimes differ. There are no clinical trials comparing warfarin and new anticoagulants (NOAC) in patients after coronary intervention, and there are also no data about the combination of NOAC with new antiaggregation drugs such as ticagrelor or prasugrel. The combination of antiaggregation (mono or dual) with NOAC or warfarin significantly increases the risk of bleeding, and therefore the intensity and the duration of treatment should be individualised and scoring systems such as CHA2DS2-VASc or HAS-BLED should be used. Anticoagulation alone (preferably NOAC) should be given to patients with chronic ischaemic heart disease (> 1 year) and atrial fibrillation.

Keywords:
atrial fibrillation – ischaemic heart disease – anticoagulation – antiagregation

Zdroje

1. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467– 1507. doi: 10.1093/ europace/ euv309.

2. Lopes RD, Pieper KS, Horton JR et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronarysyndromes with or without ST-segment elevation. Heart 2008; 94: 867– 873. doi: 10.1136/ hrt.2007.134486.

3. Rubboli A, Schlitt A, Kiviniemi T et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol 2014; 37: 357– 364. doi: 10.1002/ clc.22254.

4. Rene AG, Genereux P, Ezekowitz M et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am J Cardiol 2014; 113: 236– 242. doi: 10.1016/ j.amjcard.2013.09.016.

5. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541– 2619. doi: 10.1093/ eurheartj/ ehu278.

6. Lip GY, Windecker S, Huber K et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/ or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of CardiologyWorking Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart RhythmSociety (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155– 3179. doi: 10.1093/ eurheartj/ ehu298.

7. Gorenek B, Blomstrom Lundqvist C, Brugada Terradellas J et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace 2014; 16: 1655– 1673. doi: 10.1093/ europace/ euu208.

8. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969– 974.

9. Fiore LD, Ezekowitz MD, Brophy MT et al. Department of veterans affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105: 557– 563.

10. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001; 37: 475– 484.

11. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350: 389– 396.

12. Lip GY. Don’t add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 2008; 336: 614– 615. doi: 10.1136/ bmj.39351.706586.AD.

13. Lamberts M, Gislason GH, Lip GY et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577– 1585. doi: 10.1161/ CIRCULATIONAHA.113.004834.

14. Sorensen R, Hansen ML, Abildstrom SZ et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967– 1974. doi: 10.1016/ S0140-6736(09)61751-7.

15. Lamberts M, Olesen JB, Ruwald MH et al. Bleed-ing after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126: 1185– 1193. doi: 10.1161/ CIRCULATIONAHA.112.114967.

16. Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107– 1115. doi: 10.1016/ S0140-6736(12)62177-1.

17. Fiedler KA, Byrne RA, Schulz S et al. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-eluting stenting (ISAR-TRIPLE) study. Am Heart J 2014; 167: 459– 465. doi: 10.1016/ j.ahj.2014.01.005.

18. Oldgren J, Budaj A, Granger CB et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781– 2789. doi: 10.1093/ eurheartj/ ehr113.

19. Oldgren J, Wallentin L, Alexander JH et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013; 34: 1670– 1680. doi: 10.1093/ eurheartj/ eht049.

20. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045– 1057. doi: 10.1056/ NEJMoa0904327.

21. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001– 2015.

22. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791– 1800. doi: 10.1056/ NEJMoa1500857.

23. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397– 402. doi: 10.1001/ archinternmed.2011.1666.

24. US Food and Drug Administration DSC. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available from: http:/ /www.fda.gov/ Drugs/DrugSafety/ ucm396470.htm.

25. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9– 19. doi: 10.1056/ NEJMoa1112277.

26. Vranckx P, Verheugt FW, de Maat MP et al. A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention 2013; 8: 1052– 1060. doi: 10.4244/ EIJV8I9A162.

27. Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45– 54.

28. Alexopoulos D, Xanthopoulou I, Gkizas Vet al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797– 804. doi: 10.1161/ CIRCINTERVENTIONS.112.972323.

29. Alexander JH, Lopes RD, Thomas L et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014; 35: 224– 232. doi: 10.1093/ eurheartj/ eht445.

30. De Caterina R, Husted S, Wallentin L et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012; 59: 1413– 1425. doi: 10.1016/ j.jacc.2012.02.008.

31. Fox KA, Dabbous OH, Goldberg RJ et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333: 1091.

32. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360– 1420. doi: 10.1093/ europace/ euq350.

33. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385– 1413.

34. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903– 1912.

35. Gibson CM, Chakrabarti AK, Mega J et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 2013; 62: 286– 290. doi: 10.1016/ j.jacc.2013.03.041.

36. Čihák R, Haman L, Heinc P. Summary of the 2012 focused upadate of the ESC Guidelines for management of AF. Prepared by the Czech Society of Cardiology. Cor Vasa 2012; 54: e341– e351.

37. Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patiens treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157– 164. doi: 10.1161/ CIRCULATIONAHA.114.012061.